Shafaat Rabbani, MD - Shafaat Rabbani, MD - Research Institute MUHC
cancer • bone • metastasis • epigenetic • DNA methylation
My research focuses on determining the DNA methylation landscape of patients with breast cancer and ostoporosis. The blood based "DNA methylation signatures" will be customized as noninvasive exquisite biomarkers that will be introduced into clinical practice and change the way we predict, diagnose for therapy and follow up the progression of the disease. We are evaluating novel therapeutic and preventive approach to breast cancer metastasis based on blocking DNA demethylation processes using well established xenograft and transgenic models of breast cancer. Collectively the results from these studies will provide a molecular mechanistic basis for both prevention and treatment of breast cancer which will be translated into human clinical trials. Our group is developing novel diagnostic and therapeutic strategies to block uPA production and its interaction with cell surface uPAR to block tumor growth and metastasis. Using our well-established models of breast and prostate cancer; we are examining the efficacy of various therapeutic strategies to block tumor progression. Additionally determination of the methylation of uPA and PAI-1 is being developed as a reliable diagnostic and prognostic marker in cancer.
Parashar S, Cheishvili D, Arakelian A, Hussain Z, Tanvir I, Khan HA, Szyf M, Rabbani SA. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications. Cancer Med. 2015 May; 4(5):732-44. PMID: 25619880.
Shukeir, N, Stefanska B, Parashar S, Chik F, Arakelian A, Szyf M, Rabbani SA. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br J Pharmacol. 2015 June; 172(11):2769-81. PMID: 25631332.
Rabbani SA, Arakelian A, Farooki R. LRP5 knockdown; effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Medicine, 2:625-635, 2013. PMID: 24403228.
Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar A. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth and experimental skeletal metastasis in vitro and in vivo. Neoplasia 10:778-788, 2010. PMID: 20927316.
Rabbani, S.A., Valentino, M.L., Arakelian, A., Ali, S., Boschelli, F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth and metastasis in vitro and in vivo via regulation of genes involved in cancer growth and skeletal metastasis. Molecular Cancer Therapy, 9(5):1147-57, 2010. PMID: 20423991.